Abstract 624P
Background
Most cancer immunotherapy research focuses on gene-level expression, often bypassing the key role of alternative splicing in producing various isoform transcripts. Alternative splicing contributes significantly to tumor heterogeneity, progression, and therapy response1-3. Understanding these dynamics is paramount for advancing personalized treatment strategies.
Methods
1. Data Integration - Integrated multi-omics data from diverse tumor types. - Focused on immune cells within the tumor microenvironment. 2. Sample collection - Gathered data from both pre- and post-immunotherapy treated patients. - Included clinical response details for comprehensive insights. 3. Isoform analysis - Constructed a single-cell isoform atlas capturing the landscape of alternative splicing events and isoform expression profiles across a vast array of cancers. - Investigated patterns of isoform diversity/plasticity: - Within and between different cancer types. - Between pre- and post-treatment scenarios. - Among responders vs. non-responders.
Results
Pan-cancer isoform signatures - For each cancer type and at the pan-cancer level, the isoform patterns of immune cell types linked with oncogenic processes between (i) healthy and cancer; (ii) pre- and post-treatment; (iii) immunotherapy responders and non-responders.
Conclusions
Our pan-cancer single-cell isoform atlas offers a groundbreaking perspective on isoform dynamics in cancer immune environment, enriching our comprehension of tumor intricacies and bolstering efforts toward precision oncology for individualized patient care.
References: 1. Climente-González, H., Porta-Pardo, E., Godzik, A. & Eyras, E. The Functional Impact of Alternative Splicing in Cancer. Cell Reports 20, 2215-2226 (2017). https://doi.org:https://doi.org/10.1016/j.celrep.2017.08.012.
2. Zhang, Y., Qian, J., Gu, C. & Yang, Y. Alternative splicing and cancer: a systematic review. Signal Transduction and Targeted Therapy 6, 78 (2021). https://doi.org:10.1038/s41392-021-00486-7
3. Bonnal, S. C., López-Oreja, I. & Valcárcel, J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nature Reviews Clinical Oncology 17, 457-474 (2020). https://doi.org:10.1038/s41571-020-0350-x
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Pan.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract